|Day Low/High||7.70 / 8.05|
|52 Wk Low/High||4.45 / 8.60|
TILs Demonstrate 54% Objective Response Rate in Phase 2 Metastatic Melanoma Trial
NCI's Dr. Steven Rosenberg to Present New TIL Trial Data in Scientific Symposium
Company Remains on Track to Achieve Strategic Objectives
Research Validates More Practical, Cost-Efficient Method for TIL Manufacturing
Laszlo Radvanyi to Join Key Discussions on Cancer Immunotherapies
Grant to Fund Expanded Study of TIL Therapy With Ipilimumab
New Technologies to Enhance Tumor Infiltrating Lymphocyte Production
Facility to Focus on Development of Next-Generation TIL Technologies
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.